A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) In Patients with Advanced Cancer

ID Number 11-1358

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


This research study involves a new investigational drug, 4-demethylcholesteryl-oxycarbonylpenclomedine, also known as DM-CHOC-PEN, which has not yet been studied in humans. The purpose of this research study is to evaluate the safety, side effects, toxicities and define useful dosages for DM-CHOC-PEN as an anticancer drug.

Studies in animals show that DM-CHOC-PEN can kill cancer cells and concentrates in tumors as opposed to normal tissue. It is felt that DM-CHOC-PEN kills cancer cells by acting as an alkylating agent. An alkylating agent binds to the DNA in a cell causing lethal damage to the cell.

You may qualify to take part in this research study because you have advanced cancer that is not responding to standard therapies. It is important to note that people with blood cell derived (hematological) malignancies are not eligible for this study but people with other types of cancer may qualify.

Contact Information
(212) 824-7308
(212) 824-7293

Recruiting Patients: Yes